These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 10239821)
41. An outpatient pharmacy services benefit in a reformed health care system. Coalition for Consumer Access to Pharmaceutical Care. Am J Hosp Pharm; 1993 Jul; 50(7):1464-6. PubMed ID: 8362885 [No Abstract] [Full Text] [Related]
42. The transition from pharmacy transaction reimbursement to transaction-service reimbursement. Cole DL Med Interface; 1995 Jun; 8(6):56-7. PubMed ID: 10142943 [No Abstract] [Full Text] [Related]
43. Economics of hospital pharmacy practice. II: charging for services. Zellmer WA Am J Hosp Pharm; 1979 Mar; 36(3):307-8. PubMed ID: 420222 [No Abstract] [Full Text] [Related]
44. The Medicare Catastrophic Coverage Act of 1988 effects hospital pharmacies. Wilson CN Hosp Pharm; 1988 Nov; 23(11):1029-34. PubMed ID: 10302982 [No Abstract] [Full Text] [Related]
45. HMM drug price index advances at 4% annual rate. Hosp Mater Manage; 1987 Nov; 12(11):14-5. PubMed ID: 10285402 [No Abstract] [Full Text] [Related]
46. Cephalosporin prices rising in wake of Pryor bill. Barlow RD Hosp Mater Manage; 1991 Jul; 16(7):1, 12-3. PubMed ID: 10112311 [No Abstract] [Full Text] [Related]
47. Pharmaceutical services in a third-party system: an analysis. Donehew GR Contemp Pharm Pract; 1981; 4(4):246-52. PubMed ID: 10256900 [TBL] [Abstract][Full Text] [Related]
48. Time to reassess approaches to financing clinical pharmacy services. Curtiss FR Am J Hosp Pharm; 1983 Jul; 40(7):1146. PubMed ID: 6881147 [No Abstract] [Full Text] [Related]
50. Competition is driving down prices of many high-volume pharmaceuticals. Kuntz EF Mod Healthc; 1983 Dec; 13(12):60-2. PubMed ID: 10264040 [No Abstract] [Full Text] [Related]
51. Pharmacoeconomic considerations in rural hospitals. Lenhert P Cost Qual Q J; 1998 Jun; 4(2):37-42. PubMed ID: 10182598 [No Abstract] [Full Text] [Related]
52. Coping with Medicare Part D's effects on patient assistance programs. Askew JP Am J Health Syst Pharm; 2006 Nov; 63(22):2195-8. PubMed ID: 17090739 [No Abstract] [Full Text] [Related]
53. The pharmacist's role in prospective reimbursement. Upton JH; Crouch JB; Douglas JB South Hosp; 1983; 51(6):14, 16, 18. PubMed ID: 10273443 [No Abstract] [Full Text] [Related]
54. Billing for outpatient transplant pharmacy services. Maldonado AQ; Seiger TC; Urann CL; McCleary JA; Goroski AL; Ojogho ON Am J Health Syst Pharm; 2012 Jan; 69(2):144-7. PubMed ID: 22215360 [TBL] [Abstract][Full Text] [Related]
55. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy. Paul SH Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270 [No Abstract] [Full Text] [Related]